Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced today the initiation of a Phase 1/2 study of oral KPT-8602, a novel, second ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE